- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT03327610
Selecting the Best Ventilator Hyperinflation Settings (VHI1)
Selecting the Best Ventilator Hyperinflation Settings Based on Physiologic Markers: Randomized Controlled Study
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Background: Ventilator Hyperinflation (VHI) has been shown to be effective in improving respiratory mechanics, secretion removal, and gas exchange in mechanically ventilated patients; however, there are no recommendations on the best ventilator settings to perform the technique. Thus, the aim of this study was to compare six modes of VHI, concerning physiological markers of efficacy and safety criteria, in order to support the optimal VHI settings selection for mechanically ventilated patients.
Methods: In a crossover study, every included mechanically ventilated patient underwent six modes of VHI in a randomized order: Volume Control Continuous Mandatory Ventilation (VC-CMV) with inspiratory flow = 20Lpm (VC-CMV20), VC-CMV with inspiratory flow = 50Lpm (VC-CMV50), Pressure Control Continuous Mandatory Ventilation (PC-CMV) with inspiratory time = 1s. (PC-CMV1), PC-CMV with inspiratory time = 3s. (PC-CMV3), Pressure Support Ventilation (PSV) with cycling off = 10% of peak inspiratory flow (PSV10), and PSV with cycling off = 25% of peak inspiratory flow (PSV25). The maximum expansion (tidal volume), expiratory flow bias criteria (inspiratory and expiratory flow patterns), over-distension (alveolar pressure), asynchronies and hemodynamic variables (mean arterial pressure and heart rate) were assessed during the interventions.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Patients under mechanical ventilation for more than 48h
Exclusion Criteria:
- mucus hypersecretion (defined as the need for suctioning < 2-h intervals),
- absence of respiratory drive,
- atelectasis,
- severe bronchospasm,
- positive end expiratory pressure > 10cmH2O,
- PaO2-FiO2 relationship < 150,
- mean arterial pressure < 60mmHg,
- inotrope requirement equivalent to >15 ml/h total of adrenaline and noradrenalin,
- intracranial pressure > 20mmHg
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Sem intervenção: BASELINE
The subjects were kept in their current ventilatory mode.
|
|
Experimental: VC-CMV20
Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV) with an inspiratory flow of 20Lpm.
|
Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV).
The inspiratory flow was set at 20Lpm and the tidal volume was increased in steps of 200mL until the peak airway pressure of 40cmH2O was achieved.
After achieving the target pressure, this ventilatory regimen lasted 15 minutes.
Positive end expiratory pressure and the inspired oxygen fraction were not modified.
|
Experimental: VC-CMV50
Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV) with an inspiratory flow of 50Lpm.
|
Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV).
The inspiratory flow was set at 50Lpm and the tidal volume was increased in steps of 200mL until the peak airway pressure of 40cmH2O was achieved.
After achieving the target pressure, this ventilatory regimen lasted 15 minutes.
Positive end expiratory pressure and the inspired oxygen fraction were not modified.
|
Experimental: PC-CMV1
Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1) with an inspiratory time of 1 second.
|
Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1).
The inspiratory time was set at 1 second and the pressure control was increased until a peak pressure of 40cmH2O was achieved.
After achieving the target pressure, this ventilatory regimen lasted 15 minutes.
Positive end expiratory pressure and the inspired oxygen fraction were not modified.
|
Experimental: PC-CMV3
Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1) with an inspiratory time of 3 seconds.
|
Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1).
The inspiratory time was set at 3 seconds and the pressure control was increased until a peak pressure of 40cmH2O was achieved.
After achieving the target pressure, this ventilatory regimen lasted 15 minutes.
Positive end expiratory pressure and the inspired oxygen fraction were not modified.
|
Experimental: PSV10
Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV) with a cycling off of 10% of peak inspiratory flow.
|
Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV).
The cycling off was set at 10% of peak inspiratory flow and the pressure support was increased until a peak pressure of 40cmH2O was achieved.
After achieving the target pressure, this ventilatory regimen lasted 15 minutes.
Positive end expiratory pressure and the inspired oxygen fraction were not modified.
|
Experimental: PSV25
Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV) with a cycling off of 25% of peak inspiratory flow.
|
Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV).
The cycling off was set at 25% of peak inspiratory flow and the pressure support was increased until a peak pressure of 40cmH2O was achieved.
After achieving the target pressure, this ventilatory regimen lasted 15 minutes.
Positive end expiratory pressure and the inspired oxygen fraction were not modified.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Peak inspiratory to expiratory flow ratio
Prazo: Ten minutes after the onset of intervention.
|
Dichotomous variable, defined as achieving a peak inspiratory flow rate (PIFR) less than 90% of the peak expiratory flow rate (PEFR)
|
Ten minutes after the onset of intervention.
|
Peak expiratory flow higher than 40 Lpm
Prazo: Ten minutes after the onset of intervention.
|
Dichotomous variable, defined as achieving a PEFR higher than 40 l/min
|
Ten minutes after the onset of intervention.
|
Difference between peak inspiratory and expiratory flows.
Prazo: Ten minutes after the onset of intervention.
|
Dichotomous variable, defined as achieving a difference higher than 17Lpm.
|
Ten minutes after the onset of intervention.
|
Pulmonary expansion
Prazo: Ten minutes after the onset of intervention.
|
Percentage of tidal volume above the normal tidal volume (estimated as 6mL/kg).
|
Ten minutes after the onset of intervention.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Mean arterial pressure
Prazo: Ten minutes after the onset of intervention.
|
Mean arterial pressure verified using the multi-parameter monitor.
|
Ten minutes after the onset of intervention.
|
Heart Rate
Prazo: Ten minutes after the onset of intervention.
|
Heart rate verified using the multi-parameter monitor.
|
Ten minutes after the onset of intervention.
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Cadeira de estudo: FERNANDO S GUIMARAES, PhD, Centro Universitário Augusto Motta
Publicações e links úteis
Publicações Gerais
- Berney S, Denehy L. A comparison of the effects of manual and ventilator hyperinflation on static lung compliance and sputum production in intubated and ventilated intensive care patients. Physiother Res Int. 2002;7(2):100-8. doi: 10.1002/pri.246.
- Lemes DA, Zin WA, Guimaraes FS. Hyperinflation using pressure support ventilation improves secretion clearance and respiratory mechanics in ventilated patients with pulmonary infection: a randomised crossover trial. Aust J Physiother. 2009;55(4):249-54. doi: 10.1016/s0004-9514(09)70004-2.
- Thomas PJ. The effect of mechanical ventilator settings during ventilator hyperinflation techniques: a bench-top analysis. Anaesth Intensive Care. 2015 Jan;43(1):81-7. doi: 10.1177/0310057X1504300112.
- Ntoumenopoulos G, Shannon H, Main E. Do commonly used ventilator settings for mechanically ventilated adults have the potential to embed secretions or promote clearance? Respir Care. 2011 Dec;56(12):1887-92. doi: 10.4187/respcare.01229. Epub 2011 Jun 17.
- Anderson A, Alexanders J, Sinani C, Hayes S, Fogarty M. Effects of ventilator vs manual hyperinflation in adults receiving mechanical ventilation: a systematic review of randomised clinical trials. Physiotherapy. 2015 Jun;101(2):103-10. doi: 10.1016/j.physio.2014.07.006. Epub 2014 Oct 6.
- Davies JD, Senussi MH, Mireles-Cabodevila E. Should A Tidal Volume of 6 mL/kg Be Used in All Patients? Respir Care. 2016 Jun;61(6):774-90. doi: 10.4187/respcare.04651.
- de Wit M. Monitoring of patient-ventilator interaction at the bedside. Respir Care. 2011 Jan;56(1):61-72. doi: 10.4187/respcare.01077.
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- VHI1
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em VC-CMV20
-
University of ArizonaConcluídoDermatologia/Pele - OutrosEstados Unidos
-
National Defense Medical Center, TaiwanConcluídoDor, Aguda | Comportamento infantil | Estresse Fisiológico | Leite maternoTaiwan
-
ViaCyteCalifornia Institute for Regenerative Medicine (CIRM)RescindidoDiabetes mellitus tipo 1Canadá, Estados Unidos
-
ViaCyteRescindidoDiabetes tipo 1Estados Unidos
-
Sunnybrook Health Sciences CentreCanadian Initiative for Outcomes in Rheumatology CareRescindido
-
Queen's University, BelfastAWARE NI; Northern Ireland Public Health Research NetworkConcluído
-
University Medical Center GroningenRescindidoCâncer de esôfagoHolanda
-
ViaCyteCalifornia Institute for Regenerative Medicine (CIRM); Horizon 2020 - European...ConcluídoDiabetes mellitus tipo 1 com hipoglicemiaEstados Unidos, Canadá, Bélgica
-
ViaCyteConcluídoDiabetes mellitus tipo 1Canadá
-
VA Office of Research and DevelopmentAinda não está recrutandoDoença de obstrução pulmonar crônicaEstados Unidos